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Abstract
Background: Respiratory infections including Mycoplasma pneumoniae (Mp) contribute to various chronic lung
diseases. We have shown that mouse short palate, lung, and nasal epithelium clone 1 (SPLUNC1) protein was able
to inhibit Mp growth. Further, airway epithelial cells increased SPLUNC1 expression upon Mp infection. However,
the mechanisms underlying SPLUNC1 regulation remain unknown. In the current study, we investigated if
SPLUNC1 production following Mp infection is regulated through Toll-like receptor 2 (TLR2) signaling.
Methods: Airway epithelial cell cultures were utilized to reveal the contribution of TLR2 signaling including NF-B
to SPLUNC1 production upon bacterial infection and TLR2 agonist stimulation.
Results: Mp and TLR2 agonist Pam3CSK4 increased SPLUNC1 expression in tracheal epithelial cells from wild type,
but not TLR2
-/- BALB/c mice. RNA interference (short-hairpin RNA) of TLR2 in normal human bronchial epithelial
cells under air-liquid interface cultures significantly reduced SPLUNC1 levels in Mp-infected or Pam3CSK4-treated
cells. Inhibition and activation of NF-B pathway decreased and increased SPLUNC1 production in airway epithelial
cells, respectively.
Conclusions: Our data for the first time suggest that airway epithelial TLR2 signaling is pivotal in mycoplasma-
induced SPLUNC1 production, thus improving our understanding of the aberrant SPLUNC1 expression in airways of
patients suffering from chronic lung diseases with bacterial infections.
Background
Palate, lung, and nasal epithelium clone (PLUNC) are a
recently described family of proteins that have been pre-
dicted to exert host defense functions [1-4]. Among the
10 PLUNC proteins described so far, short PLUNC1
(SPLUNC1) has been localized to large airway epithe-
lium in humans and mice [1,5,6]. Our recent publication
suggests that recombinant mouse SPLUNC1 protein
inhibits the growth of Mycoplasma pneumoniae (Mp),
an atypical bacterium contributing to several common
respiratory diseases including community-acquired
pneumonia and asthma [7,8]. In line with our findings, a
recent study by Zhou and colleagues further revealed
that human SPLUNC1 protein impaired the growth of
Gram-negative bacterium Pseudomonas aeruginosa,a
major cause of infection in chronic lung diseases such
as cystic fibrosis [9]. However, Bartlett et al later did not
show an antimicrobial effect of recombinant human
SPLUNC1 protein on Pseudomonas aeruginosa [10].
Such discrepancy emphasizes the need to further char-
acterize the function of SPLUNC1.
To date, SPLUNC1 regulation under physiological or
pathological conditions remains poorly understood
[11-14]. We and other investigators have clearly demon-
strated the down-regulation of SPLUNC1 in human
bronchial and nasal epithelial cells by the Th2 cytokine
IL-13 [7,15]. On the other hand, Bingle and co-workers
found increased SPLUNC1 protein in airway epithelium
of patients with cystic fibrosis [16]. It remains unclear if
bacteria (e.g., Mp) or their products directly modulate
SPLUNC1 production in airway epithelial cells. If so,
what are the mechanisms underlying SPLUNC1
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gested that signaling through Toll-like receptors (TLRs)
is critical to host defense against various pathogens
including Mp [17-23]. Specifically, we demonstrated that
Mp infection in airway epithelial cells and mouse lungs
activated TLR2 signaling (e.g., increased TLR2 expres-
sion and NF-B activation). Mp infection in TLR2 defi-
cient mice failed to induce inflammatory cytokine (e.g.,
IL-6) and airway epithelial mucin production [17]. In
the current study, we hypothesize that SPLUNC1
expression is in large part under the control of TLR2
signaling (e.g., dependence on TLR2 expression and NF-
B activation). To test our hypothesis, we utilized
human and mouse airway epithelial cell cultures to
determine if TLR2 signaling is involved in SPLUNC1
expression following Mp infection or TLR2 agonist sti-
mulation. We found that airway epithelial TLR2 signal-
ing is pivotal in SPLUNC1 production.
Methods
Culture of NCI-H292 cells
A human pulmonary mucoepidermoid carcinoma cell
line NCI-H292 (ATCC, Manassas, VA) was utilized to
perform a time course and a dose response of SPLUNC1
production following Mp infection or TLR2 agonist sti-
mulation. NCI-H292 cells at 90-100% confluence were
infected with Mp at 1, 5 and 10 colony forming unit
[cfu]/cell, or stimulated with a TLR2 agonist Pam(3)-
Cys-Ser-Lys-Lys-Lys-Lys-OH (Pam3CSK4) at 10, 100
and 1000 ng/ml for up to 48 hrs. The supernatants were
collected for SPLUNC1 protein measurement using an
ELISA. Cells were lyzed in Trizol reagent (Gibco BRL,
Rockville, MD) for RNA extraction to perform quantita-
tive real-time PCR of SPLUNC1 mRNA, or processed in
cell lysis buffer to carry out Western blot analysis of
SPLUNC1 protein.
Air-liquid interface (ALI) culture of mouse tracheal
epithelial cells
ALI cultures of mouse tracheal epithelial cells were car-
ried out as previously reported by our group [24-26] to
study the direct role of TLR2 and NF-Bi nS P L U N C 1
regulation. All experimental animals used in this study
were covered by a protocol approved by our Institu-
tional Animal Care and Use Committee. Briefly, tracheas
from mice were isolated and digested with 0.1% pro-
tease, and the released cells from tracheas were plated
(about 4 × 10
4 cells/cm
2) on collagen-coated polyester
Transwell inserts of 12 mm in diameter (pore size,
0.4 μm; Corning Inc., Corning, NY, USA). After 7 days
of immersed culture, tracheal epithelial cells reached
100% confluence and were shifted to an ALI condition
by removing all but 50 μl of the apical medium.
Cells under the ALI condition are known to undergo
mucociliary cell differentiation, thus mimicking in vivo
airway epithelial cell biology. On day 10 of ALI culture,
epithelial cells were treated with Mp (10 cfu/cell, strain
FH, ATCC 15531, ATCC, Manassas, VA) at the apical
side, Pam3CSK4 (1 μg/ml, InvivoGen, San Diego, CA) at
both apical and basolateral sides, or medium alone as a
control. After 48 hrs of treatments, 200 μlo fP B Sw a s
applied to the apical surface of ALI cell culture and
incubated for 5 minutes at room temperature to obtain
the apical supernatants for SPLUNC1 protein measure-
ment using Western blot analysis.
TLR2 RNA interference in normal human bronchial
epithelial cells (NHBE)
A VSV-G pseudotyping approach was utilized to trans-
duce human TLR2 short hairpin (sh)RNA encoded in a
lentiviral vector (pLL3.7) to primary normal human
bronchial epithelial cells. The oligonucleotide sequences
that encode shRNA of hTLR2 are: Sense - 5’-T G C
AGCTCA-GGATCTTTAAATTCAAGAGATTTAAA
GATCCTGAGCTGCTTTTTTC-3’;A n t i - s e n s e-5 ’-TC
GAGAAAAAAGCAGCTCAGGATCTTTAAATCTC
TTGAATTTAAAGATCCTGAGCT-GCA-3’.N H B E
were isolated from bronchial tissues of three donors
without any lung diseases or smoking history through
the International Institute for the Advancement of Med-
icine (IIAM) (Jessup, PA). Cells at passage one were
used for lentiviral transduction experiments.
Antiparallel pairs of human TLR2 oligonucleotides
were ordered from the IDT laboratories and TLR2
shRNA encoded in pLL3.7 was generated as previously
described [7,27]. Briefly, epithelial cells were cultured in
6-well culture plates (2 × 10
5 cells/well) under the
immersed condition until about 60% confluence when
they were transduced with either pLL3.7-shTLR2 (50
focus-forming units [ffu]/cell) or pLL3.7-sh firefly luci-
ferase (an irrelevant gene control, 50 ffu/cell) once daily
for three consecutive days. Forty-eight hrs after the last
transduction, cells from each condition were collected
to verify TLR2 gene knockdown. The remaining cells
were used for ALI culture.
ALI culture of NHBE
NHBE that were transduced with either pLL3.7-shTLR2
or pLL3.7-shFirefly luciferase were cultured under ALI
conditions to determine if gene knockdown of TLR2
affects SPLUNC1 production following Mp infection or
a TLR2 agonist stimulation. ALI culture was performed
by plating the lentivirus-transduced epithelial cells onto
collagen-coated 12-well transwell plates at 4 × 10
4 cells/
cm
2 as previously reported [24]. On day 10 of ALI cul-
ture, cells were treated with Mp (10 cfu/cell),
Pam3CSK4 (1 μg/ml) or cell culture medium (control).
At 48 hr post treatments, apical supernatants were
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to measure SPLUNC1 protein levels using an ELISA.
Effects of an NF-B inhibitor on Mp-induced SPLUNC1
production
To determine the role of NF-Bi nS P L U N C 1p r o d u c -
tion, we utilized an NF-B inhibitor helenalin (Calbio-
chem, San Diego, CA) in NHBE. Briefly, NHBE at day
10 of ALI culture were pre-treated with helenalin
(10 μM in 0.1% DMSO) or 0.1% DMSO (negative con-
trol) for 2 hrs, followed by Mp (10 cfu/cell) infection or
cell culture medium (control) for 48 hrs. Apical super-
natants were collected for SPLUNC1 protein measure-
ment using an ELISA. The cells were processed for
nuclear protein extraction using a Nuclear Extract Kit
(Active Motif, Carlsbad, CA) per manufacturer’s instruc-
tion, followed by an ELISA-based assay (Active Motif)
to quantify nuclear NF-B p65 activity levels.
Direct ELISA for human SPLUNC1 protein detection
A direct SPLUNC1 ELISA was utilized to measure
human SPLUNC1 protein as previously reported by our
group [7]. Briefly, recombinant human SPLUNC1 pro-
tein and supernatants of cultured human airway epithe-
lial cells were coated onto a 96-well Immulon 2HB plate
(Fisher Scientific, Pittsburgh, PA, USA), followed by
incubations with a mouse anti-SPLUNC1 antibody
(1 μg/ml, R&D Systems), biotinylated anti-mouse anti-
body and avidin-biotin peroxidase complex. The plate
was developed using a peroxidase substrate (TMB) and
read using a plate reader.
Western blot analysis of mouse and human SPLUNC1
protein
As no ELISA is available to detect SPLUNC1 protein in
mouse samples, we utilized Western blot to quantify
SPLUNC1 protein. Briefly, 15 μl of cell culture superna-
tant was electrophoresed on 10% SDS-PAGE, transferred
onto nitrocellulose membrane, blocked with the
Western blocking buffer, and then incubated with a goat
anti-mouse SPLUNC1 antibody (R&D Systems) over-
night at 4°C. After washes in PBS with 0.1% Tween-20,
the membranes were incubated with an anti-IgG conju-
gated with a fluorescent dye (e.g., IRDye® 800), and
detected by using the Odyssey Imaging System. Densito-
metry was then performed to quantify SPLUNC1 pro-
tein levels. Intracellular SPLUNC1 protein of human
epithelial cells was similarly examined as the mouse
counterpart using the Western blot analysis.
Quantitative real-time RT-PCR
Levels of SPLUNC1 mRNA in epithelial cells were
determined by reverse transcription (RT), followed by
real-time quantitative PCR. Total RNA was extracted
using TRIzol reagent (Gibco BRL, Rockville, MD). RT
was performed using 1 μg of total RNA and random
hexamers in a 50 μl reaction (Applied Biosystems, Fos-
ter City, CA). Primers and probe for human (Genbank
accession #: NM_016583)S P L U N C 1g e n e sw e r e
designed using Primer Express software (Applied Biosys-
tems). Human SPLUNC1: forward primer, 5’-GGG
CCTGTTGGGCATTCT-3’; reverse primer, 5’-CCTC
CTCCAGGCTTCAGGAT-3’;p r o b e ,5 ’-AAACCTTC
CGCTCCTGGA- 3’. PCR was performed on the ABI
Prism 7700 sequence detection system. The 25 μlP C R
reaction contained 30 ng cDNA, 100 nM fluoregenic
probe and 200 nM primers and other components from
the TaqMan RT-PCR kit. Housekeeping gene GAPDH
was also evaluated. The comparative threshold cycle
(CT) method was employed to determine the relative
gene expression levels by using one of the control con-
ditions as the baseline level (i.e., 1) [28].
Production of recombinant human SPLUNC1 protein and
antimicrobial assay
Recombinant human SPLUNC1 protein was generated
using the baculovirus expression system. Based on the
cDNA sequence of human SPLUNC1 (Genbank acces-
sion #: NM_016583), PCR was performed using primers
containing restriction enzyme sites (EcoRI and NheI) to
generate fragments covering the entire SPLUNC1 pro-
tein. With verification of DNA sequence, the SPLUNC1
cDNA was then subcloned into a transfer vector (a
modified p479 vector with histidine cDNA at the C-
terminus) [29] to generate the recombinant SPLUNC1
baculovirus in SF9 cells to infect High-Five (Invitrogen)
insect cells to produce recombinant protein, which was
collected from the culture media, purified by using a
His-column (Promega), followed by loading the protein
onto an ion exchange column (MonoQ column) for
further purification (usually > 99% pure). The purity and
specificity of recombinant protein was confirmed by
using SDS-PAGE, Western blot and mass spectrometry.
We tested the antimicrobial activity of SPLUNC1 pro-
tein by incubating Mp (4 × 10
4 cfu/ml) with recombi-
nant human SPLUNC1 protein (1-10 μg/ml) in 96-well
tissue culture plates (100 μl SP-4 broth/well) for 2 hrs, a
typical time for bactericidal assay in Gram-negative bac-
teria. Mp in the supernatants was then plated on pleur-
opneumonia-like organism (PPLO) agar plates and
incubated at 37°C, 5% CO2 for a week to quantify Mp.
The above SPLUNC1 protein dose range selection was
based on our SPLUNC1 protein measurements in airway
epithelial lining fluid of normal human subjects (n = 12)
who had no history of respiratory diseases or cigarette
smoking, and had normal pulmonary function (e.g.,
FEV1 > 80%). The age (years) of normal subjects
(7 males and 5 females) was 33.1 ± 3.0. SPLUNC1
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subjects was measured using a direct SPLUNC1 ELISA.
After normalization of dilution factor using serum urea/
BAL urea ratio, SPLUNC1 protein concentration in air-
way epithelial lining fluid. was calculated at 5.3 ±
2.1 μg/ml.
Statistical analysis
For normally distributed data, one-way analysis of var-
iance (ANOVA) was used for multiple comparisons, and
aT u k e y ’s post hoc test was applied where appropriate.
Student’s t test was used when only two groups were
compared. Non-normally distributed data were com-
pared using the Wilcoxon rank-sum test. A p value
≤ 0.05 was considered significant.
Results
Mp or a TLR2 agonist increases SPLUNC1 expression in
NCI-H292 cells
We utilized NCI-H292 cells to study the time course
and dose response of SPLUNC1 expression following
Mp infection. Cells were infected with Mp at 1, 5 and
10 cfu/cell for 24 and 48 hrs. Mp-infected cells, as com-
pared to non-infected cells, demonstrated a significant
increase of SPLUNC1 mRNA (up to 3-fold) and protein
in a dose-dependent manner at 48 hr post infection
(Figure 1A &1B). At 24 hr, Mp did not significantly
increase SPLUNC1 expression (data not shown).
We also determined whether a TLR2 agonist was able
to up-regulate SPLUNC1 expression in NCI-H292 cells.
After 48 hrs, Pam3CSK4 at 100 and 1000 ng/ml, but
not at 10 ng/ml, significantly increased SPLUNC1 pro-
tein levels in cell supernatants (Figure 1C). Pam3CSK4
also increased SPLUNC1 mRNA in a dose-dependent
manner up to a dose at 100 ng/ml (Figure 1D). At 1000
ng/ml, Pam3CSK4 did not further increase SPLUNC1
mRNA expression.
Intracellular SPLUNC1 protein was also increased
(about 2-fold) in Mp-infected or Pam3CSK4-stimulated
cells (Figure 1E).
TLR2
-/- mouse tracheal epithelial cells fail to increase
SPLUNC1 upon Mp infection or TLR2 agonist stimulation
To demonstrate the contribution of TLR2 to airway
epithelial SPLUNC1 production following Mp infection,
TLR2
-/- and TLR2
+/+ BALB/c mouse tracheal epithelial
cells under the ALI conditions were treated with Mp or
Pam3CSK4. After 48 hrs of Mp infection or Pam3CSK4
stimulation, TLR2
+/+ tracheal epithelial cells significantly
increased SPLUNC1 protein levels in the apical superna-
tants. However, Mp infection or Pam3CSK4 treatment
in TLR2
-/- tracheal epithelial cells minimally affected
SPLUNC1 protein production (Figure 2). These results
suggest that TLR2 stimulation can directly induce
SPLUNC1 production, and an intact TLR2 signaling is
necessary for SPLUNC1 induction following Mp
infection.
SPLUNC1 regulation in NHBE
Having shown TLR2 involvement in SPLUNC1 induc-
tion upon Mp infection or Pam3CSK4 stimulation in
primary mouse tracheal epithelial cells, we tested its role
in SPLUNC1 production in NHBE by knocking-down
TLR2 expression. As shown in Figure 3, Mp infection or
Pam3CSK4 stimulation significantly increased SPLUNC1
protein in apical supernatants of well-differentiated
NHBE transduced with firefly luciferase shRNA (an irre-
levant gene control). In contrast, TLR2 shRNA-
transduced NHBE did not demonstrate an increase of
SPLUNC1 protein after Mp or Pam3CSK4 treatment.
Real-time PCR analysis demonstrated that TLR2 shRNA
transduction resulted in a 5.2-fold reduction (5.2 ± 0.3
vs. 1, p < 0.05) of TLR2 expression as compared to the
control (luciferase shRNA transduction).
Role of NF-B in SPLUNC1 regulation
Since Mp infection has been shown to increase TLR2
expression and to activate NF-B [17], we determined if
NF-B may contribute to SPLUNC1 up-regulation fol-
lowing Mp infection.
We first utilized an NF-B inhibitor helenalin in
NHBE under the ALI conditions. Helenalin is an anti-
inflammatory sesquiterpene lactone from Arnica, and
has been shown to selectively alkylate the p65 subunit
of NF-B [30]. In the absence of Mp infection, helenalin
alone did not significantly affect SPLUNC1 or NF-B
activity. However, after 24 hrs of Mp infection, helenalin
significantly reduced Mp-induced SPLUNC1 production
(Figure 4A), and tended (p = 0.07) to reduce NF-B p65
activity (Figure 4B).
T od e m o n s t r a t ead i r e c tr o l eo fN F - B pathway in
SPLUNC1 production, we performed ALI cultures of
tracheal epithelial cells from transgenic mice expressing
ad o x y c y c l i n e( D o x ) - i n d u c i b l ec o n s t i t u t i v e l ya c t i v e( C A )
version of inhibitor of B( I B) kinase-beta (IKKb)
under transcriptional control of the rat CC10 promoter
(CC10-CA-IKKb). Previous studies have shown selective
airway epithelial NF-B activation after Dox administra-
tion [31]. As shown in Figure 5, Dox treatment for
48 hrs, as compared with the control (H2O), signifi-
cantly increased SPLUNC1 levels in cells from CC10-
CA-IKKb transgene positive mice, but not in those from
the transgene negative mice.
Recombinant human SPLUNC1 protein inhibits Mp
growth
Our recent publication demonstrated that recombinant
mouse SPLUNC1 protein significantly inhibited the
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Page 4 of 10Figure 1 A dose response of SPLUNC1 production in NCI-H292 cells. Cells were cultured in 6-well plates with Mycoplasma pneumoniae (Mp,
1 - 10 cfu/cell) or a TLR2 agonist (Pam3CSK4, 10 - 1000 ng/ml) for 48 hrs, followed by collection of supernatants and cell lysates for SPLUNC1
mRNA and protein measurements, respectively. Data are expressed as means ± SEM (N = 6 replicates). (A) Mp increased SPLUNC1 protein levels
in cell supernatants in a dose-dependent manner. (B) Mp increased SPLUNC1 mRNA expression at 1 and 5 cfu/cell. (C) Pam3CSK4 at 100 and
1000 ng/ml significantly augmented SPLUNC1 protein levels in cell supernatants. ND = Not detectable. (D) Pam3CSK4 enhanced SPLUNC1
mRNA expression in a dose-dependent fashion. (E) Western blot analysis of intracellular SPLUNC1 protein and b-actin (a protein loading control)
in Mp (10 cfu/cell) and Pam3CSK4 (100 ng/ml)-treated cells using the Odyssey Imaging System (two color detection). Both Mp and Pam3CSK4
increased SPLUNC1 protein.
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ify if human SPLUNC1 protein exerts a similar activity
to the mouse counterpart in inhibiting Mp growth, we
generated recombinant human SPLUNC1 (hSPLUNC1)
protein using a baculovirus expression system. The pur-
ity and specificity of hSPLUNC1 protein were verified
by Western blot and mass spectrometry (Figure 6A and
6B). As shown in Figure 6C, hSPLUNC1 inhibited Mp
growth in a dose-dependent manner.
Discussion
Our study has provided the evidence, for the first time,
that SPLUNC1 regulation is in part under the control of
TLR2 signaling. First, we demonstrated that Mp infec-
tion and TLR2 agonist treatment increased SPLUNC1
production in wild type mouse tracheal epithelial cells,
and such an increase of SPLUNC1 was abrogated in
TLR2
-/- tracheal epithelial cells. Second, we found that
in human bronchial epithelial cell air-liquid interface
cultures, Mp and TLR2 agonist also up-regulated
SPLUNC1 production. Knockdown of TLR2 gene
expression in human bronchial epithelial cells signifi-
cantly attenuated SPLUNC1 induction following Mp
infection or TLR2 agonist stimulation.
SPLUNC1 protein is an abundantly expressed and
secreted protein in large airway epithelial cells. Elucida-
tion of function and regulation of such an abundant
protein is critical to understand the role of SPLUNC1 in
airway homeostasis and disease processes. In the current
study, we extended our previous findings that human
SPLUNC1 protein, like its mouse counterpart, exerted
inhibitory effects on Mp growth, further confirming its
host defense function.
Regulation of abundant proteins in the lung including
SPLUNC1 remains an active area of research. For exam-
ple, surfactant proteins A and D, mainly produced by
type II alveolar epithelial cells and Clara cells, are also
abundant in airway lining fluid. They play a pivotal role
in host defense against various bacterial infections.
Although certain cytokines (e.g., IL-1) and bacterial
infections are known to stimulate SP-A or SP-D produc-
tion [32,33], the direct role of TLR signaling in surfac-
tant protein regulation is poorly understood. Instead,
previous studies suggest that SP-A dampens TLR2 sig-
naling [34]. In our previous studies [7], we found that
SPLUNC1 is also able to suppress TLR2 agonist (i.e.,
Pam3CSK4)-induced IL-8 production in NCI-H292
cells. Our current study demonstrates that TLR2 signal-
ing is directly involved in SPLUNC1 up-regulation. Col-
lectively, our data suggest that TLR2 activation leads to
SPLUNC1 up-regulation, which in turn may dampen
TLR2 signaling, leading to airway homeostasis following
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Figure 2 Effects of Mycoplasma pneumoniae (Mp) and a TLR2
agonist (Pam3CSK4) on SPLUNC1 production in cultured
mouse tracheal epithelial cells. Tracheal epithelial cells from
TLR2
+/+ and TLR2
-/- mice on the BALB/c background were isolated
and cultured under the air-liquid interface (ALI) conditions for 10
days as described in the Methods section. After 48 hrs of Mp (10
cfu/cell) or Pam3CSK4 (1 μg/ml) treatment, SPLUNC1 protein levels
in apical supernatants of tracheal epithelial cells were measured
using Western blot, quantified using densitometry, and normalized
to non-treated (-) cells to obtain SPLUNC1 protein relative levels. As
compared to the non-treatment control (-), Mp or Pam3CSK4
treatment in tracheal epithelial cells from TLR2
+/+, but not TLR2
-/-
mice, significantly increased SPLUNC1 protein levels. Data are
expressed as means ± SEM (N = 3-4 replicates).
Figure 3 TLR2 dependence of SPLUNC1 production in normal
human bronchial epithelial cells (NHBE). NHBE (N = 3) were
transduced with firefly luciferase short hairpin RNA (Luc shRNA,
control) or TLR2 short hairpin RNA (TLR2 shRNA). Thereafter, cells
were seeded onto 12-well transwell plates for air-liquid interface
(ALI) culture for 10 days, and were then treated with or without
Mycoplasma pneumoniae (Mp, 10 cfu/cell) or Pam3CSK4 (1 μg/ml)
for 48 hrs. Apical supernatants were collected for SPLUNC1 protein
measurement using an ELISA. The paired t test (for normally
distributed data under Luc shRNA conditions) or Wilcoxon matched
pairs test (for non-parametric data under TLR2 shRNA conditions)
was used to analyze the treatment effect of Mp or Pam3CSK4
(Pam3) on SPLUNC1 protein levels. While Mp and Pam3CSK4
increased SPLUNC1 in NHBE transduced with Luc shRNA, they failed
to do so in TLR2 shRNA-transduced cells.
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findings have important implications in clinical settings.
For example, patients with dampened TLR2 signaling in
the airways may not be able to generate sufficient
amount of SPLUNC1 in response to an infection, and
fail to eliminate the invading pathogen and resolve
excessive inflammatory response. Indeed, we have
reported that in allergic airways or under a Th2 cytokine
milieu, lung or airway epithelial Mp clearance was
impaired with reduced TLR2 expression [35]. Thus, any
treatment aimed at appropriately enhancing TLR2
signaling in the airways has the great potential to restore
the host defense function attributed to SPLUNC1.
The functional consequences of bacterial (e.g., Mp)
infection-induced SPLUNC1 in airway mucosa need to
be robustly studied in future experiments as SPLUNC1
may have multiple functions. For example, a recent
study suggests that SPLUNC1 regulates airway surface
liquid volume by protecting epithelial Na(+) channel
(ENaC) from proteolytic cleavage [36]. Our current
study did not address the impact of Mp-induced
SPLUNC1 production on apical volume, ion transport
or ENaC activity, but these additional experiments will
be considered to advance our understanding of bacteria-
induced SPLUNC1 production. We also realize that
SPLUNC1 induction following Mp infection serves as
one of the innate defense mechanisms utilized by airway
epithelial cells to fight against the invading pathogens as
other antimicrobial substances such as lactotransferrin
can also be induced following Mp infection (unpub-
lished data from the authors’ group).
To define the mechanisms by which TLR2 signaling
regulates SPLUNC1 production, we focused on the role
of NF-B because we previously reported that Mp infec-
tion not only increased TLR2 expression, but also acti-
vated NF-B[ 1 7 ] .F i r s t ,w ef o u n dt h a ta nN F - B
inhibitor suppressed Mp-induced SPLUNC1 production
in human bronchial epithelial cells. Second, conditional
Figure 4 Effects NF-B on SPLUNC1 production in normal
human bronchial epithelial cells (NHBE). NHBE were cultured
under air-liquid interface (ALI) conditions. At day 10 of ALI culture,
cells were treated with an NF-B p65 inhibitor helenalin (10 μM)
for 2 hrs, followed by Mycoplasma pneumoniae (Mp, 10 cfu/cell)
infection for 48 hrs. (A) Helenalin inhibited Mp-induced SPLUNC1
protein at the apical surface of NHBE; (B) NF-B p65 activity was
measured in the extracted nuclear proteins of NHBE using an
ELISA-based assay (Active Motif, Carlsbad, CA). Mp significantly
increased NF-B p65 activity, which tended (p = 0.07) to be
decreased by helenalin. Data are expressed as means ± SEM (n =
3 replicates).
Figure 5 Effects NF-B pathway on SPLUNC1 production in
primary mouse tracheal epithelial cells. Tracheal epithelial cells
from CC10-tetracycline-inducible CA-IKKb (CC10-CA-IKKb) transgene
positive and negative C57BL/6 mice were isolated and cultured
under the air-liquid interface conditions for 10 days. Cells were then
treated with water (H2O) or doxycycline (Dox) for 48 hrs. SPLUNC1
mRNA in epithelial cells was quantified by using real-time PCR. As
compared to H2O treatment, Dox significantly increased SPLUNC1
mRNA levels in epithelial cells from CC10-CA-IKKb transgene positive
(Tg+), but not from transgene negative (Tg-) mice. Data are
expressed as means ± SEM (N = 4 replicates).
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cheal epithelial cells was sufficient to increase SPLUNC1
expression. Therefore, our results suggest the involve-
ment of NF-B pathway in SPLUNC1 up-regulation.
However, to further define how NF-B regulates
SPLUNC1 at the transcriptional level, more research
approaches are needed, including chromatin immuno-
precipitation (CHIP), electrophoretic mobility shift assay
(EMSA) and promoter assays using various SPLUNC1
promoter deletion mutants. We realize that NF-B path-
way may not be the sole signaling pathway responsible
for Mp- or TLR2 agonist-induced SPLUNC1 produc-
tion. Future work is warranted to better understand reg-
ulation of SPLUNC1 under other transcription factors.
For example, our preliminary data suggest that tran-
scription factor heat shock factor-1 may also contribute
to Mp-induced SPLUNC1 production.
We are aware of several limitations in the current
study. First, SPLUNC1 regulation was not investigated
in the context of other strains of bacteria that also uti-
lize TLR2 signaling. For example, nontypeable Haemo-
philus influenzae (NTHi) and Moraxella catarrhalis
Figure 6 Purity, specificity and antimicrobial activity of recombinant human SPLUNC1 protein. (A) Left-panel - Two μgo fS P L U N C 1
protein was electrophoresed on a 10% SDS-polyacrylamide gel, and then transferred onto a nitrocellulose membrane. Ponceau S staining of the
membrane showed one protein at about 25 kD (pink, black arrow). Right panel - Western blot of SPLUNC1 using the Odyssey Imaging System
verified that the 25 kD protein band shown in the left panel was SPLUNC1 (green band). (B) A representative fragmentation spectrum of
peptide LYVTIPLGIK (amino acids 129 to 138) from in-gel trypsin-digested recombinant hSPLUNC1 protein after matching algorithm using
SpectrumMill. The y-axis indicates the relative intensity of the fragment ions, where 100% is the total ion intensity of the spectrum. (C)
Recombinant human SPLUNC1 protein markedly reduced Mycoplasma pneumoniae (Mp) growth in 96-well culture plates for 2 hrs. CFUs =
Colony forming units. Data are expressed as means ± SEM (N = 5 replicates).
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Page 8 of 10(Mc) have been found in the airways of chronic lung
diseases such as chronic obstructive pulmonary disease
(COPD) [37,38]. Both NTHi and Mc have been reported
to utilize TLR2 signaling to induce inflammatory cyto-
kine responses [39,40]. These additional strains of bac-
teria will be included in our future studies. Second, the
in vivo role of airway epithelial TLR2 signaling in
SPLUNC1 production was not addressed in the current
study. This can be done by overexpressing TLR2 exclu-
sively in airway epithelial cells of TLR2
-/- mice that will
be infected with Mp or treated with a TLR2 agonist.
Third, Bingle and co-workers performed co-localization
study of SPLUNC1 with mucin MUC5AC in human air-
way tissues, and clearly demonstrated that goblet cells in
human airways do not express SPLUNC1 [16]. In the
current study, we did not focus on identifying the cellu-
lar sources of SPLUNC1. However, in our preliminary
co-localization study of SPLUNC1 and Clara cell secre-
tory protein (CCSP or CC10) in air-liquid interface cul-
tured wild-type C57BL/6 mouse tracheal epithelial cells,
some CCSP (+) cells were found to co-express
SPLUNC1 protein. Future studies are needed to clarify
the impact of TLR2 and NF-B on epithelial phenotypes
(e.g., Clara cells and ciliated epithelial cells) and asso-
ciated regulation of SPLUNC1 expression. Lastly,
SPLUNC1 secretion was measured without normaliza-
tion to the cell numbers under various cell culture con-
ditions. Future studies will be performed to normalize
SPLUNC1 secretion by cell numbers to avoid the poten-
tial impact of Mp or Pam3CSK4 on cell proliferation.
Conclusions
In summary, airway SPLUNC1 production is up-
regulated following bacterial (i.e., Mp) infection and
TLR2 agonist stimulation. Understanding the regulation
of SPLUNC1 by TLR2 signaling will help design novel
therapeutic approaches to restore SPLUNC1 levels in
hosts with allergic diseases and cigarette smoke-asso-
ciated diseases (e.g., COPD) which exhibit impaired
SPLUNC1 production [13,41].
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